FEB 12, 2019

Axcella Announces Patent Issuance for AXA Candidate AXA1125

JAN 24, 2019

Axcella Presents Mechanistic Data Demonstrating that AXA1125 Modulated Liver Metabolic, Inflammatory and Fibrotic Pathways

JAN 3, 2019

Axcella to Present Update at the 37th Annual JP Morgan Healthcare Conference

DEC 21, 2018

Axcella to Present Data on AXA1125 at Integrated Pathways of Disease in NASH and NAFLD Keystone Symposium

NOV 12, 2018

Data from Axcella’s AXA1125 Program Supports New Approach Leveraging Endogenous Metabolic Modulators to Reprogram Cellular Physiology

OCT 22, 2018

Axcella Appoints Stephen Mitchener, PharmD, to Senior Vice President, Chief Business Officer

OCT 22, 2018

Axcella to Present New Data at the Annual 2018 AASLD Liver Meeting

JUNE 27, 2018

Axcella Welcomes William D. Baird, and Cristina M. Rondinone, Ph.D., to Board of Directors

Axcella strengthens legal team with appointments of Paul F. Fehlner, J.D., Ph.D., as Senior Vice President, Chief Intellectual Property Officer and Heidy Abreu King-Jones, J.D., LL.M., as Vice President, Legal and Corporate Secretary

MAY 31, 2018

Axcella Appoints Bill Hinshaw as President and Chief Executive Officer

JAN 3, 2018

Axcella Announces Appointment of David Epstein, Former CEO of Novartis Pharmaceuticals, as Chairman of its Board of Directors

Axcella to present a corporate update at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco

SEPT 14, 2017

Axcella Appoints Manu Chakravarthy, M.D., Ph.D., as Senior Vice President, Chief Medical Officer

JUN 14, 2017

Axcella Appoints Tony Tramontin, Ph.D., as Senior Vice President, Chief Scientific Officer

APR 5, 2017

Axcella to Present at BioCentury’s 24th Annual Future Leaders in the Biotech Industry Conference

MAR 1, 2017

Axcella to Present at the Cowen and Company 37th Annual Health Care Conference



To be announced.